Drug Trial Radar · NCT06532656
Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1
Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Nov 20, 2024
Primary completion
Jul 2030
Study completion Dec 2030
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Aug 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to learn about the safety and tolerability of bictegravir (BIC)/lenacapavir (LEN) and to learn how the study drug interacts with the body in virologically suppressed (VS) children and adolescents with human immunodeficiency virus type 1 (HIV-1) on a stable and complex antiretroviral (ARV) regimen. The study will also assess the safe loading dose of LEN and pharmacokinetics (PK) of BIC/LEN. The primary objectives of this study are: * To evaluate the steady-state PK of BIC and LEN and confirm the dose of the LEN loading dose and BIC/LEN FDC in VS children and adolescents with HIV-1. * To evaluate the safety and tolerability of BIC/LEN through Week 24 in VS children and adolescents with HIV-1.
Conditions
- HIV-1-infection
Interventions
LenacapavirDrug
Tablets administered orally without regard to food
Bictegravir/Lenacapavir (BIC/LEN) FDCDrug
Tablets administered orally without regard to food
Bictegravir/LenacapavirDrug
Tablets administered orally without regard to food
Primary outcomes
What the sponsor says the trial is designed to measure.
- PK Parameter: Cmax of BIC and LEN at Steady StateTime frame: Day 1 up to Week 24, as appropriate
- PK Parameter: AUCtau of BIC and LEN at Steady StateTime frame: Day 1 up to Week 24, as appropriate
- PK Parameter: Ctrough of BIC and LEN at Steady StateTime frame: Day 1 up to Week 24, as appropriate
- Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) Through Week 24Time frame: First dose date up to Week 24
- Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Through Week 24Time frame: First dose date up to Week 24
Locations
21 sites in 5 countries. Site status is shown where the registry gives one.
Children's National Hospital
Washington D.C., District of Columbia
University of South Florida
Tampa, Florida
Grady Ponce de Leon Center
Atlanta, Georgia
Ann and Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
Helios Salud S.A
Buenos Aires, Argentina
ASST FBF Sacco Ospedale Sacco
Milan, Italy
IRCCS Ospedale Pediatrico Bambino Gesu, UOS Infezioni Complesse e Perinatali
Roma, Italy
FAMCRU Ukwanda School for Rural Health
Cape Town, South Africa
Be Part Yoluntu
Cape Town, South Africa
Durban International Clinical Research Site, Enhancing Care Foundation
Durban, South Africa
Monti Clinical Research Centre
East London, South Africa
Perinatal HIV Research Unit
Johannesburg, South Africa
Wits RHI Shandukani Research Centre CRS
Johannesburg, South Africa
Nkanyezi VIDA Research Unit
Johannesburg, South Africa
Khomanani Health Research and Wellness Centre
Ka-Majosi, South Africa
Clinical Research Institute of South Africa (CRISA)
KwaDukuza, South Africa
The Aurum Institute: Pretoria Clinical Research Centre
Pretoria, South Africa
Setshaba Research Centre
Soshanguve, South Africa
Hospital General Universitario Gregorio Marano
Madrid, Spain
Hospital Universitario 12 De Octubre
Madrid, Spain
Hospital Universitario La Paz
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.